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Background: Inherited CARD9 deficiency constitutes a primary immunodeficiency
predisposing uniquely to chronic and invasive fungal infections. Certain mutations are
shown to negatively impact CARD9 protein expression and/or NF-κB activation, but the
underlying biochemical mechanism remains to be fully understood.
Objectives: To investigate a possible founder origin of a known CARD9 R70W
mutation in five families of Turkish origin. To explore the biochemical mechanism of
immunodeficiency by R70W CARD9.
Methods: We performed haplotype analysis using microsatellite markers and SNPs.
We designed a model system exploiting a gain-of-function (GOF) CARD9 L213LI mutant
that triggers constitutive NF-κB activation, analogous to an oncogenic CARD11 mutant,
to study NF-κB signaling and signalosome formation. We performed reporter assays,
immunoprecipitation and confocal imaging on HEK cells overexpressing different CARD9
variants.
Results: We identified a common haplotype, thus providing evidence for a common
Turkish founder. CARD9 R70W failed to activate NF-κB and abrogated NF-κB activation
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byWT CARD9 and by GOF CARD9. Notably, R70WCARD9 also exerted negative effects
on NF-κB activation by CARD10, CARD11, and CARD14. Consistent with the NF-κB
results, the R70Wmutation prevented GOF CARD9 to pull down the signalosome partner
proteins BCL10 and MALT1. This reflected into drastic reduction of BCL10 filamentous
assemblies in a cellular context. Indeed, structural analysis revealed that position R70 in
CARD9 maps at the putative interface between successive CARD domains in CARD9
filaments.
Conclusions: The R70W mutation in CARD9 prevents NF-κB activation by inhibiting
productive interactions with downstream BCL10 and MALT1, necessary for assembly of
the filamentous CARD9-BCL10-MALT1 signalosome.
Keywords: CARD9 deficiency, founder mutation, BCL10, MALT1, CBM complex, NF-κB, filament, signalosome
INTRODUCTION
In the past decade, the importance of IL-17-mediated immunity
in host defense against fungal infections has become clear, in
large part by studies of patients with inborn errors of IL-
17 immunity and relentless chronic mucocutaneous candidiasis
(CMC) as a common theme. Mutations in key components of
the IL-17A/IL-17F pathway were shown to compromise cellular
responses to these cytokines, thus predisposing to CMC (1–
3). Furthermore, patients with inherited disorders affecting IL-
17A/IL-17F production (low Th17 cells) often present CMC
in combination with other infections/clinical features (1–3).
Caspase recruitment domain family member 9 (CARD9) is
an adaptor molecule connecting dectin-1 fungal sensing to
nuclear factor κB (NF-κB) signaling and thus important in
host defense against fungal infections. It was first shown that
Card9-deficient (Card9−/−) mice are highly susceptible to fungal
infection (Candida albicans) due to their inability to produce
proinflammatory cytokines in response to dectin-1 stimulation
e.g. by zymosan or C. albicans (4). Subsequently in 2009,
autosomal recessive (AR) CARD9 deficiency was identified to be
responsible for recurrent superficial fungal infections and central
invasion with Candida spp. (5).
To date, 63 patients of 38 kindreds originating from at
least 14 countries with CARD9 mutations have been reported
(see Supplemental Table 1, including references). Even though
clinical presentation is highly variable, CARD9 deficiency
predisposes uniquely to chronic and invasive fungal infections
in otherwise healthy individuals (6). As proposed in a recent
review (7), clinical presentation can be classified as (1) isolated
CMC, (2) infections of skin and subcutaneous tissues with
fungal species including Trichopython spp, Phialophora verrucosa
Abbreviations: AR, autosomal recessive; BCL10, B-cell CLL/lymphoma 10;
CARD9, caspase recruitment domain family member 9; CBM, CARD-
CC/BCL10/MALT1; CC, coiled-coil; CMC, chronic mucocutaneous candidiasis;
Co-IP, co-immunoprecipitation; GOF, gain-of-function; IBD, Identity-by-descent;
LOF, loss-of-function; LTT, lymphocyte transformation test; MALT1, mucosa-
associated lymphoid tissue lymphoma translocation protein 1; NF-κB, nuclear
factor kappa-light-chain-enhancer of activated B cells; PMA, phorbol 12-myristate
13-acetate; PWM, pokeweed mitogen; SNP, single-nucleotide polymorphism; WT,
wild-type.
and Corynespora cassiicola, and (3) systemic fungal disease
manifesting primarily as meningoencephalitis, osteomyelitis and
intra-abdominal infections with Candida spp, Trichophyton
spp, Exophiala spp, and rarely Aspergillus (5–10). All patients
are homozygous or compound heterozygous for 21 different
mutations in the CARD9 CARD and coiled-coil (CC) domains
(Figure 2A, Supplemental Table 1). Most of these mutations
are missense and nonsense mutations, but also frameshifts,
synonymous substitutions and an in-frame deletion have been
described.
CARD9 is an intracellular adaptor molecule that mediates
signaling downstream of C-type lectin receptors, including
Dectin-1 and Dectin-2, upon fungal recognition by myeloid
or epithelial cells. CARD9 forms signaling complexes with
B-cell CLL/lymphoma 10 (BCL10) and mucosa-associated
lymphoid tissue lymphoma translocation protein 1 (MALT1),
termed CARD-CC/BCL10/MALT1 (CBM) complexes. Such
CBM signalosomes mediate NF-κB activation resulting in
induction of pro-inflammatory cytokines, such as IL-1, IL-6,
and IL-23. These promote the differentiation of T lymphocytes
into IL-17 producing T cells, further mediating anti-fungal
immunity (7).
Caspase recruitment domains (CARD) are the common motif
in the CARD subfamily of death domain proteins containing 33
human CARD-containing proteins. Homotypic CARD-CARD
domain interactions between CARD-proteins regulate the
assembly of many signaling complexes, including the CBM
signalosome and many others such as the apoptosome and the
inflammasome (11). CARD9 belongs to a phylogenetically
distinct family of CARD-proteins along with CARD10
(CARMA3), CARD11 (CARMA1), and CARD14 (CARMA2)
which are defined by their CARD and coiled-coil (CC) domains
(11, 12). The four different CARD-CC proteins all form CBM
signaling complexes, mediated mainly by CARD-domain
hetero-multimerization. CBM complexes form a critical link
between cell-surface receptors that associate with extracellular
molecular antigens and downstream activation of NF-κB. Active
CBM signalosomes are formed when pre-existing filamentous
BCL10 structures are nucleated by activation of CARD-CC
proteins (13–15). Genetic defects in several components of the
CBM complex have been linked to human immunopathology.
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Somatic and germline gain-of-function (GOF) mutations in
CARD11, MALT1, and BCL10 cause B cell lymphomas and
lymphoproliferative disorders (16). Biallelic loss-of-function
(LOF) mutations in CARD11, MALT1, and BCL10 lead to
combined immunodeficiencies (16–18) whereas the here-
discussed CARD9 deficiency predisposes exclusively to fungal
infections.
The R70W (c.208C>T) CARD9 mutation was previously
reported in four patients of three unrelated families of
consanguineous Turkish decent, living in Belgium or France
(10, 19). We here expand the R70WCARD9 cohort to 11 patients
of five unrelated families all from Turkish descent and we provide
evidence supporting a common founder origin of this mutation.
The R70W CARD9 variant was shown to affect CARD9 protein
expression and is associated with impaired NF-κB activation (10).
In this study, we interrogated the biochemical mechanism of the
R70W mutation in CARD9 and found that it disrupts NF-κB
activation by abrogating recruitment of BCL10 and subsequent
filamentous signalosome formation.
MATERIALS AND METHODS
Patients
Patients were recruited in Ghent University Hospital, Ghent,
Belgium (19); University Hospital ULB Erasme, Brussels,
Belgium; Saint Pierre University hospital, ULB, Brussels,
Belgium; University Hospital Saint Luc, UCL, Brussels, Belgium;
the Infectious Diseases Unit in Bretonneau Hospital, Tours,
France and Necker Hospital, Paris, France (10). This study was
conducted in accordance with the Helsinki Declaration and was
approved by the ethical committee of Ghent University Hospital
(2012/593). All patients and their relatives provided written
informed consent for participation in the study.
Extended case reports are provided in the online supplement.
T-Cell Proliferation
T-cell proliferation assay was a standard lymphocyte proliferation
test (LTT) performed in routine immunology laboratories.
Responses to C. albicans and the mitogens phytohemaglutinin
(PHA), Concanavalin A (ConA), or Pokeweed mitogen (PWM)
were assessed.
Immunologic Assessment of Th17
Function and Fungal Recognition
For intracellular cytokine staining, 1∗106 PBMC were cultured in
complete medium with phorbol 12-myristate 13-acetate (PMA)
(200 ng/mL) and Ionomycin (1µg/mL) in the presence of
Brefeldin A (20µg/mL) (all from Sigma). Cells were stained
with CD4T cell surface markers (CD3, CD4, CD45RO), fixed
and then stained intracellularly for IL-17A (eBio64dec17) and
IFNg (4s.B3, eBioscience). IL-17+ cells were scored within
CD3+CD4+CD45RO+ cells. In addition, IL-17 production
upon stimulation with SEB or PMA/ionomycin was measured by
ELISA.
To test fungal recognition, 2∗105 PBMC were cultured for 2
days in complete medium without or with heat-killed Candida
albicans (Invivogen, 10µg/mL). ELISA for IL-6 was performed
on supernatants (eBioscience Ready-Set-Go).
Haplotype Analysis
Genomic DNA was isolated from whole blood cells according
to standard procedures. Identity-by-descent (IBD) mapping was
carried out in two affected individuals (F2 III:2, III:3) from family
2 by genome-wide single-nucleotide polymorphism (SNP) arrays
using the HumanCytoSNP-12 BeadChip platform (Illumina,
San Diego, CA). Ten IBD regions (>1Mb) were identified
using PLINK software (20). Starting from the IBD region
(3.3Mb) encompassing CARD9, four microsatellite markers
were selected using NCBI Map Viewer (including genetic maps
deCODE, Généthon, Marshfield and Rutgers Map v.3). In
addition, five tagging SNP markers (UCSC Table Browser)
were genotyped to further delineate the common haplotype.
Primers were designed with Primer3Plus. Fragment analysis and
sequencing were performed on the ABI 3730XL DNA Analyzer
(Applied Biosystems). Data analysis of the microsatellite markers
was performed with the GeneMapper v5 software (Applied
Biosystems) and SNP markers were analyzed with SeqScape
v2.5 (Life Technologies). Microsatellite and SNP markers were
genotyped for haplotype analysis in ten affected patients and
eleven healthy family members of the five families.
Cloning and Mutagenesis
Plasmids of the cloned genes were deposited in the
LMBP/GeneCorner plasmid collection for public access
along with detailed descriptions of cloning strategy and plasmid
sequence (http://www.genecorner.ugent.be). Identification of
the conserved site corresponding to the oncogenic CARMA1
L225LI (L232LI in long splice form) mutation was done in a
MUSCLE multiple sequence alignment of a wide selection of
CARD-CC proteins from Cnidaria to humans using UGENE
(21). A pcDNA3-Flag (LMBP: 9609) or pENTR3C (LMBP: 9877)
clone of human CARD9 was used as a template to generate
the R70W (LMBP: 10266), L213LI (LMBP: 10178) and the
R70W/L213LI (LMBP: 10265) mutants by PCR with Universe
High-Fidelity Hot Start Taq (Bimake).
Two truncated CARD9 variants were generated. One
downstream of the first CC domain CARD9-Q295X (LMBP:
10532) found in 11 patients and one downstream of the second
CC domain CARD9-E419X (LMBP: 10457) constructed based on
the last residue of the CC domain.
To test the effect of R70W CARD9 on the other CARD-CC
proteins, analogously auto-actived mutants were generated
by introducing a premature stop codon in between the CC-
domain and the downstream C terminal inhibitory domain:
CARD9-E419X (LMBP: 10457), CARD10-1C (LMBP: 10459),
CARD11-1C (LMBP: 10458), and CARD14-1C (LMBP:
10460).
Cell Culture, Transfection, and Expression
Analysis
MALT1 deficient HEK293T cells (generated in house, clone
#36) (22) were grown under standard conditions (DMEM,
10% FCS, 5% CO2, 37
◦C) and transfected with the calcium
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phosphate method (23). For NF-κB reporter assays, the indicated
CARD9 construct was co-transfected with an NF-κB-dependent
luciferase reporter expression plasmid (LMBP: 3249) and
an actin promoter-driven β-galactosidase expression plasmid
(LMBP: 4341) as transfection control. The cells were washed
with PBS and lysed in luciferase lysis buffer (25mM Tris
pH7.8, 2mM DTT, 2mM CDTA, 10% glycerol, 1% Triton X-
100). For the colorimetric determination (at 595 nm) of β-
galactosidase activity, chlorophenol red-β-D-galactopyranoside
(CPRG) (Roche diagnostics) was used as a substrate. Luciferase
activity was measured by using beetle luciferin (Promega)
as a substrate and luminescence was measured with the
GloMax R© 96 Microplate Luminometer (Promega). Luciferase
data processing was done in LibreOffice (www.libreoffice.
org) Calc. For evaluation of the MALT1-dependent signaling
effects, the CARD9 clones were co-transfected with the NF-κB
luciferase reporter and β-galactosidase expression plasmids in the
MALT1 deficient HEK293T cells with or without reconstitution
with human MALT1 (LMBP: 5536). For immunoprecipitation
experiments, E-tagged human BCL10 (LMBP: 9637) and human
MALT1 were co-transfected with the different CARD9 clones.
Cells expressing BCL10 and MALT1 but no Flag-tagged
CARD9 construct were used as background control for the
immunoprecipitation. Immunoprecipitation was performedwith
anti-Flag antibody (F-3165, Sigma) in IP buffer (25mM HEPES
pH 7.5, 150mM NaCl, 0.2% NP-40, 10% glycerol) with protein
G magnetic Dynabeads (Invitrogen). For immunoblot detection,
MALT1 was detected by a rabbit monoclonal antibody (EP603Y,
Abcam), BCL10 with rabbit anti-E-tag antibody (ab66152,
Abcam) and CARD9 with mouse anti-Flag antibody (F-3165,
Sigma) or anti-Flag-HRP (A-8592, Sigma). All western blots
were developed on an Odyssey scanner (LI-COR) except for
HRP, which was developed with an Amersham Imager 600
(GE). For studies of inducible interactions of WT CARD9
with BCL10 and MALT1, transfected HEK293T cells were
treated with 200 ng/ml PMA for 30 minutes before lysis and
immunoprecipitation.
Structural Analysis of CARD9 and
Structural Context of R70W CARD9
A structural model for human CARD9 was initially created from
structure-based sequence alignments of the sequence encoding
the CARD domain of human CARD9 (uniprot Q9H257) and
was further improved via models computed via I-TASSER and
QUARK (24). The homology model of the CARD domain of
CARD9was docked into a three-dimensional model representing
the human BCL10 filament (Electron Microscopy Data Base
code EMD-5729; (15) using the segment fitting algorithms
implemented in Chimera (25).
Confocal Imaging
HEK293T cells were seeded in 8-well chamber slides (Ibidi).
Ninety percent confluent cells were transfected using
polyethylenimine [PEI, 25kDa branched (26)] with Flag-
CARD9 and E-BCL10 (150 ng plasmid DNA each per well).
The next day, cells were fixed with 4% PFA and were stained
with mouse anti-Flag-tag (Sigma F3165) and rabbit anti-E-tag
(Abcam ab66152) in triton containing staining buffer. Primary
antibodies were detected using donkey anti-mouse-AF594 and
donkey anti-rabbit 650.
Confocal images were captured with a Zeiss LSM880 confocal
microscope (Zeiss, Zaventem, Belgium). Images were taken using
a 63 × Pln Apo/1.4 oil objective. The pinhole was set at 1Airy
Unit and scans ware made with a pixel dwell time of 2.62 µs. The
scan area covered 800 by 800 pixels. Combined with a zoom of 2.2
this resulted in a pixel size of 0.077µm. A Z-stack of 40–50 slices
was recorded with a z-interval of 0.6µm. 3D reconstructions
were made in the 3D opacity mode of Volocity 6.3 (Perkin
Elmer).
Statistical Analysis
Graphpad Prism was used to perform one-way ANOVA
analysis followed by Tukey’s post-hoc testing to assess statistical
significance of the reporter assay data.
RESULTS
Clinical Presentation Is Highly Variable in
the R70W CARD9 Patient Cohort
We studied a cohort of 11 patients all harboring a known
missense mutation in CARD9: R70W (c.208C>T). Family
trees are provided in Figure 1. Because all patients originated
from the Turkish provinces Afyonkarahisar and Eskis¸ehir,
we suspected a founder effect. Indeed, haplotype analysis
provided evidence for a common Turkish founder (Figure 2B,
Supplemental Figure 1).
Despite all bearing the R70W CARD9 mutation, the
11 patients present various fungal infections, including
isolated CMC, chronic and invasive dermatophytosis, Candida
meningoencephalitis and osteomyelitis, and intra-abdominal
infections with C. albicans and Aspergillus spp (Table 1).
Extra-pulmonary aspergillosis was only recently associated with
AR CARD9 deficiency in 2 children (9). We here present an
additional patient, F2 I.2, who reported to be healthy until
she presented with retro-peritoneal aspergillosis at age 48.
Consistent with previous reports (7, 10), the severity of the
phenotype increases with age in the R70W CARD9 cohort, with
childhood CMC often pre-dating invasive infections. This was
also the case for patient F3 II.2, who developed CMC at age 36
and C. albicans encephalitis at age 39.
Routine immunological work up revealed generally normal
T and B cell subsets in all patients (Table 1). Lymphocyte
proliferation upon stimulation with C. albicans was decreased
in 5 out of 8 patients tested. Five patients displayed elevated
serum IgE levels and 4 had eosinophilia. Th17 function
was significantly decreased in 7 out of 10 patients tested.
Pro-inflammatory cytokine production upon Candida
stimulation was decreased in 6 out of 8 patients available
for testing. Neither of the parameters reflecting anti-fungal
immunity (Th17, anti-candida response) correlated with disease
severity. Detailed case reports can be found in the online
supplement.
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FIGURE 1 | Pedigrees. CARD9 R70W mutations were identified in five families.
Each kindred is identified by a number (F1–F5), each generation by a Roman
numeral (I–V), and each subject by an Arabic numeral (1–12). Square, circle
and diamond shapes indicate male, female, and sex unknown, respectively. A
double line represents reported consanguinity. Diagonal lines indicate
deceased individuals. Filled symbols represent affected individuals, clear
symbols represent unaffected individuals. The index patients are indicated with
arrows. Where available, the genotype is mentioned. WT, wild-type allele.
R70W CARD9 Does Not Activate NF-κB and
Inhibits NF-κB Activation by WT CARD9
and a Gain-of-Function CARD9 Mutant
Upon overexpression, wild-type (WT) CARD9 only moderately
induced NF-κB activity in MALT-1-deficient HEK293T cells,
but this was promoted by MALT-1 co-expression (27). Indeed,
overexpression of WT CARD9 induced a 2- to 4-fold increase of
MALT-1-dependent NF-κB reporter activity (Figures 3A,B,D).
The R70Wmutant, however, did not exhibit MALT-1-dependent
NF-κB activation. More importantly, upon co-transfection of
WT and R70W, the R70Wmutant exerted an inhibitory effect on
MALT-1-dependent NF-κB activation induced by WT CARD9
(Figures 3A,B). Off note, protein expression of the R70W allele
was often weaker than the WT CARD9 allele, as had been
reported before (10). We here report only data from those
experiments where protein expression of R70W CARD9 was
comparable to WT.
In that earlier report studying R70W CARD9 (10), co-
expression of upstream (Dectin-1, Syk) and downstream
(BCL10) signaling proteins together with fungal stimulation
was used to determine the effects of CARD9 mutations on
NF-κB activation. In that system of upstream activation, the
R70W mutant also exhibited impaired NF-κB signaling. This
strategy may also activate endogenous CARD10 present in
HEK293T cells due to the high sequence conservation of
the CARD-domain, which could mask effects of CARD9
mutations. To avoid this potential confounding factor and to
specifically study signaling events downstream of CARD9, we
generated a gain-of-function (GOF) mutant analogous to an
oncogenic constitutively active CARD11 L225LI mutant. Like
other oncogenic mutations in CARD11, this mutation is situated
in the CC-domain and triggers constitutive NF-κB activation
(17). The isoleucine insertion site is highly conserved ever since
the single ancestral CARD-CC protein in the last common
vertebrate ancestor (Supplemental Figure 2) and allowed us to
generate an analogous isoleucine insertion mutant in CARD9
(L213LI). This CARD9 GOF mutant shows dramatically higher
induction of NF-κB activity compared to WT, which we used
as a model system for CARD9 activation, to test the effect of
the R70W mutation. The L213LI CARD9 constitutive NF-κB
activation was completely suppressed by the R70W mutation
both in co-transfection of single mutants and in a double mutant
setup (L213LI/R70W) (Figures 3C,D). Upon co-transfection, the
double mutant also substantially reduced NF-κB activation by
the GOF mutant but not as dramatically as the R70W single
mutant. Since the protein expression of the R70W/L213LI double
mutant was significantly lower than the other CARD9 alleles
despite equal DNA dosage, this indicated a dose-dependency of
the R70W inhibiting effect. Indeed, a cross-over dose-titration of
the GOF L213LI mutant and the R70W/L213LI double mutant,
confirmed such dose-dependency (Figure 3E). Importantly, at a
1:1 DNA ratio (reminiscent of heterozygosity) there was still 22%
residual NF-κB activation.
Considering the known structural homology and the potential
for functional redundancy between CARD-CC proteins, we
also assessed the effect of R70W CARD9 on auto-active
mutants of CARD10, CARD11, and CARD14, all lacking the
C-terminal inhibitory domain (Figure 4A). Surprisingly, upon
co-transfection R70W CARD9 repressed NF-κB activity by all 4
auto-active CARD-CC proteins.
The proposed mechanism of the L225LI mutation in CARD11
is that it blocks intramolecular auto-inhibition from an inhibitory
domain in the linker between the CC and the C-terminal
domain (17). To investigate whether the sequence downstream
of the CC domain(s) in CARD9 acts as an inhibitory domain
in an analogous manner, we generated CARD9 constructs
harboring a premature stop after the first CC (295∗) and the
second CC (419∗). As expected, the two truncated forms show
elevated activity compared to WT CARD9, indicating a common
activation mechanism among CARD-CC proteins (Figure 4B).
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FIGURE 2 | CARD9 structure and haplotype analysis of the R70W (c.208C>T) mutation. (A) Schematic CARD9 gene structure and reported disease-associated
mutations. Roman numbered boxes represent exons. Gray boxes situate the CARD and Coiled Coil domains at protein level. The R70W mutation is shown in bold,
the gain-of-function L213LI mutation in red. (B) Segregation analysis of flanking microsatellites and single nucleotide polymorphisms revealed a common haplotype of
1.03Mb. Patients codes refer to the pedigrees in Figure 1. Segregation of the haplotype in all available family members is shown in Supplemental Figure 1. M,
mutant allele; F, family.
The Q295∗ mutation and similar Q289∗ are the two most
commonmutations occurring in patients with CARD9 deficiency
(11 and 15 patients, respectively) (Supplemental Table 1). Auto-
activation had already been shown for the Q295∗ mutant (10) but
we here propose the mechanism behind that observation.
R70W CARD9 Disrupts Downstream NF-κB
Signaling by Inhibiting BCL10 Recruitment
and Filamentous Network Formation
To elucidate the underlying mechanism prohibiting R70W
CARD9 from activating NF-κB, we studied its interactions
with BCL10 and MALT1, which together with CARD9 form
filamentous CBM complexes. As previously shown (28), without
upstream activation, WT CARD9 failed to pull down BCL10
and MALT1, despite its activation of NF-κB in the reporter
assays, presumably because that latter assay is more sensitive.
To verify WT CARD9 could be activated by upstream stimuli,
we used a setup similar to Figure 3A, but with upstream
activation by PMA that activates protein kinase C upstream of
CARD9. The results show that WT CARD9 is able to pull-down
BCL10 and MALT1 upon activation (Supplemental Figure 3).
Despite a decreased protein expression for the CARD9 mutants
(Supplemental Figure 4), but in line with the reporter assay
results, the GOF CARD9 mutant was exclusively able to pull-
down BCL10 and MALT1. The R70W mutant did not pull
down BCL10 and MALT1 and inhibited the GOF mutant to
do so in the double mutant setup (Figure 5A), thus revealing
that BCL10 recruitment is impaired by the R70W mutation.
To rationalize the functional impact of the R70W mutation
in CARD9 and to obtain complementary mechanistic insights,
we leveraged structural information regarding the assembly
principles of filamentous BCL10 and the CARD11-BCL10-
MALT1 signalosome (15). N-terminal CARD domains sharing
strong conservation in sequence and structure, constitute a
hallmark of signalosome proteins, and are responsible for
the ability of such proteins to oligomerize into intracellular
filamentous structures (13–15). Given the paucity of structural
information for the CARDdomain of CARD9, we took advantage
of the high sequence and structural homology shared by CARD
domains to create a homology model for the CARD domain of
CARD9 (Supplemental Figure 5 and main Figure 5B). In the
first instance, this revealed that position R70 maps to the end
of helix 4 (α4) at the surface of the helical CARD9 scaffold
(Figure 5B). Therefore, we reasoned that radical mutation of R70
to a tryptophan (grantham score = 101), as is the case in the
identified R70W CARD, could be deleterious for the ability of
CARD9 to interact either with itself to form filaments, or to
annex to BCL10 filaments to nucleate signaling-competent CBM
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FIGURE 3 | R70W CARD9 inhibits NF-κB transcriptional activity. (A, C) Schematic summaries of the experimental conditions in (B,D) respectively, adjusted from (13).
(B, D) MALT1-deficient HEK293T cells were transfected with WT, R70W, L213LI and R70W/L213LI CARD9 as indicated, with fixed total DNA quantities, with or
without MALT1 as indicated, together with an NF-κB-dependent luciferase reporter expression plasmid and a constitutively expressed β-galactosidase reporter gene.
Luciferase values were normalized against β-galactosidase and expressed as fold induction compared to WT CARD9 without MALT1. Expression of MALT1 and
CARD9 protein measured by western blot are shown below the graphs. (E) WT HEK293T cells were co-transfected with decreasing doses of L213LI DNA and
increasing doses of R70W/L213LI CARD9 DNA (ng/well, doses specified under graph). The total DNA amount was kept constant at 400ng/well. Luciferase values
were expressed as fold induction compared to L213LI CARD9 alone. All values under the dotted line are significant.Results shown in (B,D,E) are mean +/- standard
deviation of 4 replicates. One out of 2–3 representative experiments is shown. Statistical analysis was performed on reporter assay data with one-way ANOVA and
Tukey’s multiple comparison’s (B, D, E) post-testing. The most relevant statistical differences are shown, a list of all p-values is provided in
Supplemental Tables 2–4. p < 0.001 (***) in all panels, in (B,D) only for reporter assays with MALT1 reconstitution.
signalosomes, or to interact with other partner proteins. Indeed,
modeling of CARD9-CARD structures into the BCL10-CARD
filament as revealed by electron microscopy (15), indicates that
position R70 localizes at the heart of the interfaces of consecutive
CARD9-CARD modules within the helical filament (Figure 5C).
Thus, mutation of this position to any amino acid residue, and in
particular to a radically different amino acid in terms of structural
and chemical properties such as tryptophan, will be expected to
abrogate the ability of CARD9-CARD to mediate filamentous
forms of the protein.
Looking for evidence to substantiate our in silico predictions,
we performed confocal imaging on HEK293T cells transfected
with Flag-CARD9 and E-BCL10. Wild-type CARD9 was
found as a diffuse signal neighboring BCL10 filaments, which
were polarized at one side of the nucleus (Figure 5D left
panel). Compared to WT, the GOF L213LI CARD9 mutant
induced a clustering of CARD9 in dense spheroid structures
ornamenting an intricate network of branched BCL10 filaments
that stretched all over the cellular body (Figure 5D middle
panel). In contrast, the GOF/LOF double mutant CARD9
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FIGURE 4 | CARD9 premature stop mutants reveal the presence of an N-terminal auto-inhibition domain (A). NF-κB luciferase reporter assay of R70W CARD9
co-transfected with auto-active mutants of CARD9, CARD10, CARD11, and CARD14, all lacking the C-terminal inhibitory domain. Luciferase values were expressed
as fold induction compared to WT CARD9 alone. (B) NF-κB luciferase reporter assay of CARD9 constructs, harboring a premature stop after the first CC (Q295*) and
the second CC (E419*) domain. Results shown in both panels are mean +/- standard deviation of 4 replicates. Statistical analysis was performed on reporter assay
data with one-way ANOVA and Tukey’s multiple comparison’s post-testing. The most relevant statistical differences are shown: each CARD protein compared with
and without CARD9 R70W in (A) and each mutant compared to WT CARD9 in (B). A list of all p-values is provided in Supplemental Tables 5, 6. ***p < 0.001.
failed to form a BCL10 network. Despite concentration of
CARD9 in spheroid structures, suggesting that CARD9 itself
was activated, the BCL10 filaments remained polarized at one
side of the nucleus and failed to form a branched network all
over the cell (Figure 5D right panel). This demonstrates that
the R70W mutation indeed abrogates filamentous signalosome
formation.
DISCUSSION
The adaptor protein CARD9 connects C-type lectin-receptor
signals to the CBM signalosome to activate NF-κB upon
fungal recognition by myeloid cells. Biallelic CARD9 LOF
mutations are associated with a wide range of fungal
infections (Supplemental Table 1) and the here described
R70W CARD9 patient cohort displays the same heterogeneity.
This demonstrates that the nature of fungal infections a patient
suffers from, is not determined by the type of CARD9 mutation.
The degree and severity of the presenting phenotype vary
considerably between affected individuals and seem to aggravate
with age with CMC always preceding invasive fungal disease
(except in the case of F2 I:2 for whom this is unknown). Hence,
an early diagnosis and accurate prophylaxis and follow-up are
imperative to prevent CARD9 deficient patients from developing
invasive infections.
The presence of a CARD9 R70W founder mutation in
the Turkish population from Afyonkarahisar/Eskis¸ehir might
simplify the laboratory diagnosis of CARD9 deficiency by
targeted sequencing of the third exon. However, other mutations
could be prevalent in that same population, since at least three
patients of Turkish origin (though not precisely defined from
which region) have been described with a Q295∗ nonsense
mutation (exon 6) and a clinical presentation similar to
the patients described in this manuscript (29, 30). Targeted
resequencing of the R70W mutation in 68 healthy Turkish
individuals from the Istanbul region (results not shown) showed
that the allele was absent there, suggesting that it may be
geographically confined to the rural provinces of Afyonkarahisar
and Eskis¸ehir, where a tradition of consanguineous marriages
promotes passing on of recessive disease (31). At this moment,
we have no evidence that the R70W CARD9 mutation would
provide any beneficial traits to the population, and its presence
could thus be a direct consequence of endogamy within a small
and genetically homogenous population, where a detrimental
recessive allele became common through the founder effect
(32, 33). Earlier research has already shown a common founder
origin for another CARD9 mutation [Q289∗; (7)] of middle-
eastern origin, which raises the idea that CARD9 heterozygosity
may offer a certain protective effect in populations from the
greater Mediterranean basin. Larger genetic studies looking at
carriership of rare CARD9 variants in this and other populations
may provide more substance to this hypothesis.
We confirmed earlier observations that R70W CARD9 fails
to activate NF-κB (10). In addition, we uncovered that this is
because the R70W mutation disrupts the interaction with the
critical downstream signaling proteins, BCL10 and MALT1, thus
preventing the formation of CBM signalosomes.
Remarkable was the inhibitory effect of the R70W allele
seen in vitro upon co-transfection with WT and GOF CARD9,
which stands in sharp contrast to the absence of symptoms
in heterozygous R70W carriers. The lack of phenotype in
heterozygous carriers can be explained by a dose-dependent
activation of NF-κB. This is supported by previous observations
(10) and our own that the R70W allele has a tendency to
produce less protein compared to WT. From our dose-response
curves, we know that the R70Wmutation, when expressed in the
double mutant with the GOF allele, at a 1:1 DNA ratio with the
GOF single mutant, leaves about 22% residual NF-κB activity.
Translated to heterozygotes, such residual NF-κB activity could
explain the absence of disease. Based on the low expression levels
of the R70W allele that we (Supplemental Figure 4) and others
(10) observed, heterozygotes would have a relative expression of
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FIGURE 5 | R70W CARD9 fails to pull down BCL10 and MALT1 and inhibits BCL10 filamentous network formation. (A) WT HEK293T cells were co-transfected with
MALT1 and E-tagged BCL10 with indicated Flag-tagged CARD9 constructs. The CARD9 variants were immunoprecipitated with anti-Flag antibody and
co-immunoprecipitation of BCL10 and MALT1 was detected (“IP”, upper panel) by anti-E-tag (BCL10) and anti-MALT1 antibody. CARD9 was detected with
anti-Flag-HRP antibody. Input controls as immunoblotted on total lysate are shown in the lower panel. Density quantification of CARD9 on the total lysates is shown in
Supplemental Figure 4. (B) A structural model for human CARD9 was created from structure-based sequence alignments of the sequence encoding the CARD
domain of human CARD9 (uniprot Q9H257) and further improved computed via I-TASSER and QUARK. The R70 residue is depicted in red. (C) The homology model
of the CARD domain of CARD9 was docked into a three-dimensional model representing the human BCL10 filament using the segment fitting algorithms
implemented in Chimera. (D) E-tagged BCL10 was co-transfected with indicated Flag-tagged CARD9 constructs in un-stimulated HEK293T cells. Confocal imaging
was performed with anti-E (BCL10, Green) and anti-Flag (CARD9, Red). 3D reconstructions of 50 Z-stacks are shown. Scale bar = 10µm.
WT/mutant CARD9 somewhere in the range of 70/30 or higher,
hence even more residual NF-kB activity could be suspected.
The key to the profound inhibiting effect of R70W CARD9
lies in the structural data, which revealed that position R70
in CARD9-CARD maps at the interface between successive
CARD domains in CARD9 filaments. We have illustrated the
dramatic impact of R70W CARD9 that is intrinsically unable to
participate in CARD9 and BCL10 filaments to seed signalosome
assembly in a cellular context. This is in line with previous
observations that many of the BCL10-CARD and CARD11-
CARD interfacial residues are crucial for BCL10 polymerization
as well as CARD11-CBM complex formation-induced NF-κB
activation (15). The same study further demonstrates how
CARD11 nucleates BCL10 filaments in order to form an active
CBM signalosome (15). They propose a scenario in which
CARD11 forms short helical segments to nucleate BCL10
segments using its coiled-coil domain. Our high resolution
confocal data corroborate that scenario of short spheroid-like
segments. Most missense disease-causing mutations, like R70W,
are situated in the CARD9 CARD- and CC-domains. Along the
scenario proposed by Qiao et al., these mutations are highly
likely to abolish BCL10 filamentous network formation. Such
profound inhibition against WT proteins is a characteristic of
mutants of highly oligomeric assemblies (15, 34), such as the
inflammasome adaptor Apoptosis-associated speck-like protein
(ASC), where ASC mutants with a non-functional CARD only
assemble filaments but not specks, thus inhibiting formation of
functional inflammasomes (35).
Our structural insights rationalize the use of the L213LI GOF
mutant. Like many lymphoma-related mutations (17), it maps
to the coiled-coil. Along the Qiao scenario, its gain-of-function
action thus derives likely both from overcoming auto-inhibition
and by enhancing oligomerization (18). The use of this GOF
mutant as a model for the in vitro activation of CARD9 in
HEK293T cells, allowed us to observe a much stronger inhibitory
effect of the R70W mutant allele in comparison to an upstream
activation model (10). The GOF CARD9 model system focuses
on CARD9-CBM NF-κB activation, whereas upstream stimuli,
be it Dectin1-ligation or PMA, would also activate endogenous
other CARD-CC proteins (CARD10 in case of HEK293T cells)
or alternative pathways, thereby possibly masking the full effect
of the R70W allele.
The different CARD-CC proteins are to some extent
functionally redundant: CARD10 was shown to be able to
Frontiers in Immunology | www.frontiersin.org 11 October 2018 | Volume 9 | Article 2366
De Bruyne et al. CARD9 Deficiency Disrupts NF-κB Signaling
complement CARD11 deficiency in T cells (36), and there
is evidence for CARD14-mediated zymosan signaling in
keratinocytes (27). The R70W CARD9 allele also inhibited NF-
κB activation by the three other CARD-CC proteins, CARD10,
CARD11, and CARD14. This confirms the profound negative
behavior of R70W CARD9 and demonstrates that hetero-
multimerization can occur in the formation of a signaling-
competent CBM signalosome. In vivo, however, CARD9
expression is confined to myeloid cells whereas CARD11 is
expressed in lymphocytes and CARD10 and CARD14 mainly in
different non-immune cells (www.biogps.org). These cell-type-
specific expression profiles of the different CARD-CC proteins
make it unlikely that a LOF CARD9 mutant would be able to
influence the other CARD-CC signaling pathways in vivo. This
is supported by the absence of symptoms others than fungal
infections in CARD9 deficient patients.
The GOF CARD9 model system can be useful for future
functional characterization of other disease-associated CARD9
mutations, as we illustrated for the Q295∗ allele. The method is
however not without limitations, since disease-causingmutations
that influence the response of CARD9 to upstream activating
signals would be expected to leave a GOF CARD9 mutant
unaffected. In that case, co-expression of CARD9 mutants
with upstream signaling components would still be the best
option.
In conclusion, we here expand the R70W CARD9 cohort to
11 patients of five unrelated families from Turkish descent and
provide evidence supporting a common founder origin of this
mutation. We demonstrate that the R70W mutation disrupts
the interaction with the critical downstream signaling partners
BCL10 and MALT1, thus prohibiting the formation of CBM
signalosomes and NF-κB signaling.
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